Current status, challenges and perspectives in the development of vaccines against yellow fever, dengue, Zika and chikungunya viruses.

Emerging and re-emerging viral infections transmitted by insect vectors (arthopode-borne viruses, arbovirus) are a serious threat to global public health. Among them, yellow fever (YFV), dengue (DENV), chikungunya (CHIKV) and Zika (ZIKV) viruses are particularly important in tropical and subtropical regions. Although vector control is one of the most used prophylactic measures against arboviruses, it often faces obstacles, such as vector diversity, uncontrolled urbanization and increasing resistance to insecticides. In this context, vaccines may be the best control strategy for arboviral diseases. Here, we provide a general overview about licensed vaccines and the most advanced vaccine candidates against YFV, DENV, CHIKV and ZIKV. In particular, we highlight vaccine difficulties, the current status of the most advanced strategies and discuss how the molecular characteristics of each virus can influence the choice of the different vaccine formulations.

[1]  K. Pierce,et al.  Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. , 2011, Vaccine.

[2]  P. Repik,et al.  Development of an attenuated strain of chikungunya virus for use in vaccine production. , 1986, Vaccine.

[3]  A. Barrett.  Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease. , 2017, Vaccine.

[4]  Chao Shan,et al.  Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease , 2017, Cell.

[5]  Jairo Lizarazo,et al.  Guillain-Barré Syndrome Associated with Zika Virus Infection in Colombia. , 2016, The New England journal of medicine.

[6]  R. Baric,et al.  Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection , 2017, Emerging infectious diseases.

[7]  G. Benelli,et al.  Declining malaria, rising of dengue and Zika virus: insights for mosquito vector control , 2016, Parasitology Research.

[8]  S. Higgs,et al.  Prior Exposure to Zika Virus Significantly Enhances Peak Dengue-2 Viremia in Rhesus Macaques , 2017, Scientific Reports.

[9]  L. von Seidlein,et al.  The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan , 2016, PLoS medicine.

[10]  A. Durbin.  Vaccine Development for Zika Virus—Timelines and Strategies , 2016, Seminars in Reproductive Medicine.

[11]  R. G. Carvalho,et al.  [Aedes aegypti control strategies: a review]. , 2016, Epidemiologia e Serviços de Saúde.

[12]  Shu-Fen Wu,et al.  Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. , 2003, Vaccine.

[13]  Daniel Lucey,et al.  Congenital Zika Syndrome in 2017. , 2017, JAMA.

[14]  Mary E. Wilson,et al.  Chikungunya fever: an epidemiological review of a re-emerging infectious disease. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  G. Screaton,et al.  Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus , 2016, Nature Immunology.

[16]  P. Imperato.  The Convergence of a Virus, Mosquitoes, and Human Travel in Globalizing the Zika Epidemic , 2016, Journal of Community Health.

[17]  G. Carrasquilla,et al.  Efficacy of a tetravalent dengue vaccine in children in Latin America. , 2015, The New England journal of medicine.

[18]  A. Barrett.  Zika vaccine candidates progress through nonclinical development and enter clinical trials , 2016, npj Vaccines.

[19]  R. Lourenço-de-Oliveira,et al.  Genome analysis of yellow fever virus of the ongoing outbreak in Brazil reveals polymorphisms , 2017, Memorias do Instituto Oswaldo Cruz.

[20]  Marko Kolenc,et al.  Zika Virus Associated with Microcephaly. , 2016, The New England journal of medicine.

[21]  J. Mascola,et al.  Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. , 2016, Cell reports.

[22]  Yee‐Shin Lin,et al.  Antibodies from dengue patient sera cross‐react with endothelial cells and induce damage , 2003, Journal of medical virology.

[23]  T. Monath,et al.  Yellow fever vaccine , 2005, Expert review of vaccines.

[24]  G. Mann,et al.  The yellow fever 17D vaccine virus: molecular basis of viral attenuation and its use as an expression vector. , 1997, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[25]  M. Theiler,et al.  Modification of the virulence of yellow fever virus by cultivation in tissues in vitro , 1936 .

[26]  W. Chiu,et al.  A chikungunya fever vaccine utilizing an insect-specific virus platform , 2016, Nature Medicine.

[27]  J. Crowe,et al.  Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site , 2015, Journal of Virology.

[28]  Stephanie A Booth,et al.  In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine , 2016, npj Vaccines.

[29]  G. Benelli,et al.  Current vector control challenges in the fight against malaria. , 2017, Acta tropica.

[30]  C. Tacket,et al.  Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. , 2000, The American journal of tropical medicine and hygiene.

[31]  D. Resnik.  Ethical issues in field trials of genetically modified disease-resistant mosquitoes. , 2014, Developing world bioethics.

[32]  P. Pitisuttithum,et al.  Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial , 2014, The Lancet.

[33]  J. T. August,et al.  A DNA Vaccine against Yellow Fever Virus: Development and Evaluation , 2015, PLoS neglected tropical diseases.

[34]  S. Higgs,et al.  A VLP vaccine for epidemic Chikungunya virus protects non-human primates against infection , 2010, Nature Medicine.

[35]  N. Hynes,et al.  The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model , 2016, Science Translational Medicine.

[36]  J. H. Strauss,et al.  Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Metselaar.  [Arboviruses]. , 2012, Nederlands tijdschrift voor geneeskunde.

[38]  T. Monath,et al.  An inactivated cell-culture vaccine against yellow fever. , 2011, The New England journal of medicine.

[39]  Nicholas Jackson,et al.  Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. , 2015, The New England journal of medicine.

[40]  L. Shek,et al.  Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. , 2016, The Journal of infectious diseases.

[41]  Hugh H. Smith,et al.  THE EFFECT OF PROLONGED CULTIVATION IN VITRO UPON THE PATHOGENICITY OF YELLOW FEVER VIRUS , 1937, The Journal of experimental medicine.

[42]  N. Lurie,et al.  Considerations for Developing a Zika Virus Vaccine. , 2016, The New England journal of medicine.

[43]  J. H. Bauer,et al.  The transmission of yellow fever to Macacus rhesus , 2001 .

[44]  C. Huang,et al.  Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. , 2011, Vaccine.

[45]  Yan Li,et al.  Adaptive Diversification Between Yellow Fever Virus West African and South American Lineages: A Genome-Wide Study. , 2017, The American journal of tropical medicine and hygiene.

[46]  Saravudh Suvannadabba,et al.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial , 2012, The Lancet.

[47]  Roger E. Thomas.  Yellow fever vaccine-associated viscerotropic disease: current perspectives , 2016, Drug design, development and therapy.

[48]  C. Huang,et al.  Molecular determinants of dengue virus 2 envelope protein important for virus entry in FcγRIIA-mediated antibody-dependent enhancement of infection. , 2014, Virology.

[49]  S. Halstead.  Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge , 2016, The American journal of tropical medicine and hygiene.

[50]  D. Hume,et al.  Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity , 2015, Science Translational Medicine.

[51]  C. Huang,et al.  Attenuation Markers of a Candidate Dengue Type 2 Vaccine Virus, Strain 16681 (PDK-53), Are Defined by Mutations in the 5′ Noncoding Region and Nonstructural Proteins 1 and 3 , 2000, Journal of Virology.

[52]  A. Barrett,et al.  Research and development of Zika virus vaccines , 2016, npj Vaccines.

[53]  F. Guirakhoo,et al.  Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine , 2001, Journal of Virology.

[54]  T. Ishikawa,et al.  A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. , 2014, Vaccine.

[55]  D. Beasley,et al.  Status of research and development of vaccines for chikungunya. , 2016, Vaccine.

[56]  C. Carrington,et al.  Understanding the evolution and spread of chikungunya virus in the Americas using complete genome sequences , 2017, Virus evolution.

[57]  E. Gould,et al.  Factors responsible for the emergence of arboviruses; strategies, challenges and limitations for their control , 2015, Emerging Microbes & Infections.

[58]  A. D. de Silva,et al.  Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus , 2017, Nature Communications.

[59]  J. Mascola,et al.  Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial , 2014, The Lancet.

[60]  G. Fröschl,et al.  Serotype influences on dengue severity: a cross-sectional study on 485 confirmed dengue cases in Vitória, Brazil , 2016, BMC Infectious Diseases.

[61]  M. Diamond,et al.  Vaccination strategies against Zika virus. , 2017, Current opinion in virology.

[62]  Yee‐Shin Lin,et al.  Anti-dengue virus nonstructural protein 1 antibodies recognize protein disulfide isomerase on platelets and inhibit platelet aggregation. , 2009, Molecular immunology.

[63]  J. Mascola,et al.  Rapid development of a DNA vaccine for Zika virus , 2016, Science.

[64]  S. M. Costa,et al.  DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus. , 2006, Vaccine.

[65]  S. Cherian,et al.  Antiviral Perspectives for Chikungunya Virus , 2014, BioMed research international.

[66]  A. P. Adams,et al.  Attenuation of Chikungunya Virus Vaccine Strain 181/Clone 25 Is Determined by Two Amino Acid Substitutions in the E2 Envelope Glycoprotein , 2012, Journal of Virology.

[67]  K. Hanley,et al.  Viral Load and Cytokine Response Profile Does Not Support Antibody-Dependent Enhancement in Dengue-Primed Zika Virus–Infected Patients , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[68]  F. Falkner,et al.  Pre-Clinical Efficacy and Safety of Experimental Vaccines Based on Non-Replicating Vaccinia Vectors against Yellow Fever , 2011, PloS one.

[69]  Max Theiler,et al.  THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION , 1937, The Journal of experimental medicine.

[70]  G. Benelli,et al.  Mosquito vectors of Zika virus , 2017 .

[71]  M. Beltramello,et al.  Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection , 2016, Science.